Trial · NCT00584857
A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
NCT00584857, Phase 2, Completed, University of Alabama at Birmingham; results first posted 2012-03-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer. Trials, record NCT00584857. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00584857
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
- NCT number
- NCT00584857
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 30 participants, actual
- Lead sponsor
- University of Alabama at Birmingham
- Conditions
- Uterine Cancer
- Interventions
- Paclitaxel ,Carboplatin , Megesterol Acetate
- First posted
- 2008-01-02
- Last updated
- 2017-01-27
- Results first posted
- 2012-03-29
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 3-year Overall Survival | 3 years - median followup of 40.4 months | Number of subjects alive at 3 years |
| Secondary | Toxicity | 3 years | Toxicity secondary to paclitaxel, carboplatin, and megesterol acetate based on NCI common toxicity criteria |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 3-year Overall Survival | 3 years - median followup of 40.4 months | partipants | NUMBER | |
| SECONDARY | Toxicity | 3 years | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 3-year Overall Survival | Paclitaxel/Carboplatin/Megesterol Acetate | 17 | partipants | ||
| Toxicity | Paclitaxel/Carboplatin/Megesterol Acetate | 5 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Paclitaxel/Carboplatin/Megesterol Acetate | 30 | |
| Overall Study | COMPLETED | Paclitaxel/Carboplatin/Megesterol Acetate | 30 | |
| Overall Study | NOT COMPLETED | Paclitaxel/Carboplatin/Megesterol Acetate | 0 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | deep vein thrombosis | Vascular disorders | Paclitaxel/Carboplatin/Megesterol Acetate | 3 | 30 | 3 |
| serious | port fracture | Surgical and medical procedures | Paclitaxel/Carboplatin/Megesterol Acetate | 1 | 30 | 1 |
| serious | pulmonary embolism | Respiratory, thoracic and mediastinal disorders | Paclitaxel/Carboplatin/Megesterol Acetate | 1 | 30 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Paclitaxel/Carboplatin/Megesterol Acetate | ||
| Total, other adverse events | Paclitaxel/Carboplatin/Megesterol Acetate | 0 | 30 |
| Total, serious adverse events | Paclitaxel/Carboplatin/Megesterol Acetate | 5 | 30 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24724218 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00584857
GET https://conductscience.org/api/trials/v1/NCT00584857/registered